The Effects of Ripasudil in Patients With FED Undergoing Femtosecond Laser Assisted Cataract Surgery
Key facts
- Who runs it
- Singapore Eye Research Institute
- Where
- Singapore1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Recruiting
- Phase
- Phase 3
- People taking part
- 120 people, planned
- Started
- 1 Mar 2025
- Planned end
- Jul 2025
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Ripasudil
- Placebo
- Record updated
- 29 January 2025
Who can take part
- Age
- 50 years to 100 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 9 criteriaShow less
Who can take part
- Patients with FED who will be listed for cataract surgery as part of standard clinical practice (A cataract will be defined as clouding of the lens that interferes with normal vision)
- Only patients older than 50 years will be included, as cataracts develops with increasing age. No gender criteria are applied
- Ability to provide informed consent, and are willing and able to sign a written Informed Consent Form prior to any study-specific procedures
- Patients must be willing and able to return for scheduled follow-up examinations for up to 12 months after the surgery
Who cannot take part
- Patients who have previous allergic reactions to the contents present in Glanatec Ophthalmic solution 0.4%
- Diagnosis of clinically relevant eye diseases that may interfere with the aim of the study
- History of ripasudil use, as well as other systemic disease such as cardiovascular or renal disease
- Patients who are unable to give consent
- An only-functioning eye in a patient who has lost visual potential in the contralateral eye
The main criteria, as questions
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 50 and 100 years old?
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The purpose of this research is to investigate the effects of ripasudil administered as an ophthalmic solution in patients with FED after femtosecond laser assisted cataract surgery. The secondary aim is to identity the characteristics of patients who will benefit the most with the use of ripasudil based on the test results obtained from this study.
The 2 groups in the trial
- TreatmentTreatment being tested
Participants in this group will be asked to instill Glanatec Ophthalmic Solution (containing Ripasadil 0.4%) 4 times a day for 1 month following cataract removal surgery.
Treatment: Ripasudil
- PlaceboPlacebo, for comparison
Participants in this group will be asked to instill saline solution 4 times a day for 1 month following cataract removal surgery.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- The Effects of Ripasudil in Patients With Fuchs Endothelial Corneal Dystrophy Undergoing Femtosecond Laser Assisted Cataract Surgery
- Criteria questions
- Built from NCT06048380, who can take part
- Record updated
- 29 January 2025